| Addressing Depression and Positive Parenting Techniques (ADAPT) (NCT04298437) | Centre for Addiction and Mental Health | 2022-05-01 |
| Improving Social, Emotional, Behavioral, and Academic Functioning (NCT05425381) | East Carolina University | 2022-02-01 |
| Navigating Resource-Constrained Systems and Communities to Promote the Behavioral Health of Black Youth (NCT04113161) | Washington University School of Medicine | 2020-01-01 |
| Clinical and Social Trajectories of Children and Adolescents With Disruptive Behavior (NCT02812537) | Hospices Civils de Lyon | 2019-05-20 |
| Mindful Parenting and Parent Training Program Study (NCT03796663) | New York University | 2018-12-18 |
| Mindfulness-based Program for Children With Disruptive Behavior Disorder (NCT03698240) | IRCCS Fondazione Stella Maris | 2018-10-04 |
| Personalizing Psychosocial Intervention for Children With Disruptive Behaviour (NCT07495683) | Centre for Addiction and Mental Health | 2016-09-01 |
| Behavioral Sleep Intervention in Children With Disruptive Behaviors (NCT02783560) | Indiana University | 2016-05-01 |
| Enhancing the Outcomes of a Behavioral Parent Training Intervention (NCT02704221) | Christina Studts | 2016-03-01 |
| Strongest Families Finland Canada: Family-based Prevention and Treatment Program of Early Childhood Disruptive Behavior (NCT01750996) | IWK Health Centre | 2011-10-01 |
| Addressing Behaviour and Treatment Effectiveness Project (A.B.A.T.E. Project) (NCT02488499) | Centre for Addiction and Mental Health | 2010-07-01 |
| A Study of the Safety of Risperidone in the Treatment of Children and Adolescents With Conduct and Other Disruptive Behavior Disorders (NCT00236470) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2002-01-01 |
| A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation (NCT00250354) | Janssen Pharmaceutica N.V., Belgium | 1997-09-01 |
| A Study of the Safety and Effectiveness of Risperidone Versus Placebo for the Treatment of Conduct Disorder in Children With Mild, Moderate, or Borderline Mental Retardation (NCT00266552) | Janssen Pharmaceutica N.V., Belgium | |